Table 4. Multivariate analysis of objective response.
| Variable | Coefficient | p-value |
|---|---|---|
| L-OHP ≥ 70% | −0.39 | 0.39 |
| CPT-11 ≥ 75% | 1.02 | 0.031 |
| 5-FU (bolus) > 0% | −0.70 | 0.021 |
| 5-FU (duration) ≥ 80% | −0.083 | 0.87 |
| Sex: Female | −0.60 | 0.050 |
| Age ≥ 65 years | −0.12 | 0.70 |
| Disease status (vs. local) | ||
| Metastatic | 0.46 | 0.25 |
| Recurrent | −0.13 | 0.79 |
| History of therapy | −0.16 | 0.65 |
| ECOG PS | −0.51 | 0.13 |
| G-CSF use | 0.53 | 0.14 |
| UGT1A1 (Ref: Wild) | ||
| Single variant | 0.14 | 0.63 |
| Double variant | −0.55 | 0.51 |
| CA19-9* | −0.22 | 0.46 |
| Albumin* | −0.28 | 0.45 |
| CRP* | 0.33 | 0.46 |
*continuous value.
Abbreviations: L-OHP, oxaliplatin; CPT-11, irinotecan, 5-FU, fluorouracil; ci, continuous infusion; ECOG PS, Eastern Cooperative Oncology Group Performance status; G-CSF, granulocyte-colony stimulating factor; CA19-9, carbohydrate antigen 19-9; CRP, C-reactive protein.